PDF herunterladen
Semin Respir Crit Care Med 2000; Volume 21(Number 05): 375-384
DOI: 10.1055/s-2000-9400
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Economic Issues in Lung Cancer

Louise Bordeleau1,26 , Pamela J. Goodwin1,3-6
  • 1Department of Medicine, University of Toronto, Toronto, Canada
  • 2Toronto-Sunnybrook Regional Cancer Centre, Toronto, Canada
  • 3Division of Clinical Epidemiology at the Samuel Lunenfeld Research Institute, University of Toronto, Toronto, Canada
  • 4Mount Sinai Hospital, Toronto, Canada
  • 5the Clinical Epidemiology and Health Care Research Program
  • 6University of Toronto, Toronto, Canada
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

    Lizenzen und Reprints

ABSTRACT

The purpose of this study is to review the economics of lung cancer management. The economic literature that relates to the diagnosis, treatment, and palliation of lung cancer as well as the pertinent methodological literature were reviewed. Lung cancer treatment is moderately expensive. The overall cost to society is significant given its high incidence. The cost of staging lung cancer can be minimized through the judicious use of diagnostic and staging procedures. The cost-effectiveness of combined modality therapy and palliative chemotherapy for lung cancer appears reasonable when compared with commonly accepted medical interventions. Based on this review, current approaches to lung cancer diagnosis and treatment are, for the most part, cost-effective. Reasons for inconsistent practice patterns in the management of lung cancer in the medical community should be further explored.

KEYWORD

Lung cancer - costs - decision-making

REFERENCES

  • 1 Parker S L, Toug T, Bolden S, Wingo P. Cancer statistics 1996.  CA Cancer J Clin . 1996;  65 5-27
    PubMedSuche in Google Scholar
  • 2 National Cancer Institute of Canada. Canadian Cancer Statistics 1997. Toronto, Canada, National Cancer Institute of Canada, 1997
  • 3 Vergnenègre A, Perol M, Pham E, the GFPC (Group Francais Pneumo Cancérologie). Cost analysis of hospital treatment-two chemotherapeutic regimens for non-surgical non-small cell lung cancer.  Lung Cancer . 1996;  14 31-44
    CrossrefPubMedSuche in Google Scholar
  • 4 Palmer A J, Brandt A. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective.  Monaldi Arch Chest Dis . 1996;  51 279-288
    PubMedSuche in Google Scholar
  • 5 Govert J A, Kopita J M, Matchar D, Kussin P S, Samuelson W M. Cost-effectiveness of collecting routine cytologic specimens during fiberoptic bronchoscopy for endoscopically visible lung tumor.  Chest . 1996;  109 451-456
    CrossrefPubMedSuche in Google Scholar
  • 6 Black W C, Armstrong P, Daniel T M. Cost effectiveness of chest CT in T1N0M0 lung cancer.  Radiology . 1988;  167 373-378
    PubMedSuche in Google Scholar
  • 7 Eddy R J. Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer.  J Can Assoc Radiol . 1989;  40 189-193
    PubMedSuche in Google Scholar
  • 8 The Canadian Lung Oncology Group. Investigation for mediastinal disease in patients with apparently operable lung cancer.  Ann Thorac Surgery . 1995;  60 1382-1389
    PubMedSuche in Google Scholar
  • 9 Gambhir S S, Hoh C K, Phelps M E, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma.  J Nuc Med . 1996;  37 1428-1436
    PubMedSuche in Google Scholar
  • 10 Colice G L, Birkmeyer J D, Black W C, Littenberg B, Silvestri G. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases.  Chest . 1995;  108 1264-1271
    PubMedSuche in Google Scholar
  • 11 Richardson G E, Venzon D J, Phelps R, Edison M, Brown M, Frame J N, Ihde D C, Johnson B E. Application of an algorithm for staging small-cell lung cancer can save one-third of the initial evaluation costs.  Arch Intern Med . 1993;  153 329-337
    CrossrefPubMedSuche in Google Scholar
  • 12 Rosenthal M A, Webster P J, Gebski V J, Stuart-Harris R C, Langlands A O, Boyages J. The cost of treating small cell lung cancer.  Med J Aust . 1992;  156 605-610
    PubMedSuche in Google Scholar
  • 13 Evans W K, Will B P, Berthelot J-M, Wolfson M C. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model.  Can J Oncol . 1995;  5 408-419
    PubMedSuche in Google Scholar
  • 14 Goodwin P J, Feld R, Evans W K, Pater J. Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer.  J Clin Oncol . 1988;  6 1537-1547
    PubMedSuche in Google Scholar
  • 15 Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.  New Engl J Med . 1991;  325 164-170
    CrossrefPubMedSuche in Google Scholar
  • 16 Glaspy J A, Bleecker G, Crawford J, Stoller R, Strauss M. The impact of therapy with figrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.  Eur J Cancer . 1993;  29A(suppl 7) S23-S30
    PubMedSuche in Google Scholar
  • 17 Lyman G H, Lyman C G, Sanderson R A, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.  J Natl Cancer Inst . 1993;  85 488-493
    PubMedSuche in Google Scholar
  • 18 Nichols C R, Fox E P, Roth B J, Williams S D, Loehrer P J, Einhorn L H. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.  J Clin Oncol . 1994;  12 1245-1250
    PubMedSuche in Google Scholar
  • 19 Jaakkimainen L, Goodwin P J, Pater J, Warde P, Murray N, Rapp E. Counting the costs of cancer chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.  J Clin Oncol . 1990;  8 1301-1309
    PubMedSuche in Google Scholar
  • 20 Kennedy W, Reinharz D, Tessier G, Contandriopoulos A-P, Trabut I, Champagne F, Ayoub J. Cost utility of chemotherapy and best supportive care in non-small cell lung cancer.  PharmacoEconomics . 1995;  8 316-323
    PubMedSuche in Google Scholar
  • 21 Evans W K, Will B P, Berthelot J M, Wolfson M C. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.  Br J Cancer . 1995;  72 1270-1277
    PubMedSuche in Google Scholar
  • 22 Evans W K, Will B P, Berthelot J M, Wolfson M C. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model.  Can J Oncol . 1995;  5 408-419
    PubMedSuche in Google Scholar
  • 23 Evans W K. Cost-effectiveness of vinorelbine alone or vinorelbine plun cisplatin for stage IV NSCLC.  Oncology . 1998;  3 18-26
    PubMedSuche in Google Scholar
  • 24 Evans W K, Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.  Eur J Cancer . 1996;  32A 2249-2255
    PubMedSuche in Google Scholar
  • 25 Earle C C, Evans W K. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer.  Cancer Prev Contr . 1997;  1 282-288
    PubMedSuche in Google Scholar
  • 26 Hillner B E, Smith T J. Overview of economic analysis of Le Chevalier vinorelbine study.  Oncology . 1998;  12 14-17
    PubMedSuche in Google Scholar
  • 27 Smith T J, Hillner B E, Neighbors D M, McSorley P A, Le Chevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.  J Clin Oncol . 1995;  13 2166-2173
    PubMedSuche in Google Scholar
  • 28 Earle C C, Evans W k. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.  Br J Cancer . 1999;  80 815-820
    CrossrefPubMedSuche in Google Scholar
  • 29 Laupacis A, Feeny D, Detsky A S, Tugwell P X. How attractive does a new technology have to be to warrant adoption with utilization?.  <~>Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J . 1992;  146 473-481
    PubMedSuche in Google Scholar
  • 30 Laupacis A, Feeny D, Detsky A S, Tugwell P X. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J .  1993;  148 927-929
    PubMedSuche in Google Scholar
  • 31 Bordeleau L, Earle C C, Will B P, Coyle D, Berthelot J-M, Evans W K. A decision-making framework for chemotherapeutic interventions for advanced non-small cell lung cancer.  J Natl Cancer Inst. in press; 
    PubMedSuche in Google Scholar
  • 32 Evans W K. An estimate of the cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer.  Semin Oncol . 1996;  23 82-89
    PubMedSuche in Google Scholar
  • 33 Copley-Merriman C, Corral J, King K, Whiteside R, Voi M, Dorr A, McDonald R C. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.  Lung Cancer . 1996;  14 45-61
    CrossrefPubMedSuche in Google Scholar
  • 34 Williamson S K, Crowley J J, Livingston R B, Panella T J, Goodwin J W. Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study.  Invest New Drugs . 1995;  13 67-71
    PubMedSuche in Google Scholar
  • 35 Evans W K, Will B P, Berthelot J-M, Earle C C. Cost of combined modality interventions for stage III non-small-cell lung cancer.  J Clin Oncol . 1997;  15 3038-3048
    PubMedSuche in Google Scholar
  • 36 Evans W K, Will B P, Berthelot J-M, Wolfson M C. The economics of lung cancer management in Canada.  Lung Cancer . 1996;  14 19-29
    CrossrefPubMedSuche in Google Scholar
  • 37 Desch C E, Hillner B E, Smith T J. Economic considerations in the care of lung cancer patients.  Curr Opin Oncol . 1996;  8 126-132
    PubMedSuche in Google Scholar
  • 38 Weeks J. Overview of outcomes research and management and its role in oncology practice.  Oncology . 1998;  12 11-13
    PubMedSuche in Google Scholar
  • 39 Smith T J. A piece of mind. Which hat do I wear?.  JAMA . 1993;  270 1657-1659
    CrossrefPubMedSuche in Google Scholar
  • 40 Smith T J, Hillner B E, Desch C E. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis.  J Natl Cancer Inst . 1993;  85 1460-1474
    PubMedSuche in Google Scholar
  • 41 Raby B, Pater J, Mackillop W J. Does knowledge guide practice?.  <~>Another look at the management of non-small-cell lung cancer. J Clin Oncol . 1995;  13 1904-1911
    PubMedSuche in Google Scholar